Skip to main
  1. Stocks
  2. BioAge Labs Inc.
  3. Forecast
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is attractive because BGE-102 targets NLRP3, an upstream inflammatory node that may offer broader and more durable disease control than distal cytokine blockade, while Phase 1 data already showed about a 90% reduction in IL-1β and an 80% to 90% reduction in hsCRP. Its lead program has multiple near-term catalysts, with QUELL-CV enrollment completed and topline expected in 4Q26, plus QUELL-DME now using a 180-patient, three-arm design with BCVA as the primary endpoint and topline expected in 2H27. Financially, the company reported $352.3 million in cash, cash equivalents, and marketable securities as of September 30, 2026, supporting a runway through 2029 and reducing near-term dilution risk while the data story develops.

Bears say

Bioage Labs is burdened by widening losses, with 3Q26 net loss rising to $33.5 million from $20.2 million in 3Q25 as R&D climbed to $30.2 million, reflecting heavier BGE-102 spending and still-limited collaboration revenue of just $0.3 million. Its lead programs face demanding clinical and regulatory hurdles: QUELL-CV is only now in a 160-patient, 12-week cardiovascular study, QUELL-DME is a harder 180-patient visual-acuity trial against anti-VEGF control, and no NLRP3 inhibitor has been approved while hsCRP remains an unproven surrogate. The stock also carries meaningful dilution and valuation risk, with $381.3 million in cash at June 30, 2026 but a modeled need to raise $200 million in FY27E, while competition from better-capitalized peers and a valuation tied entirely to explicit FY27E to FY45E forecasts limit downside protection.

BIOA has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.

BIOA Analyst Forecast & Price Prediction

Get the latest BIOA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BIOA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc. (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 9 analysts, BIOA has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc. (BIOA)


BIOA Analyst Forecast & Price Prediction

Get the latest BIOA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BIOA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BIOA stock data and trends